8-K: Annexon posts FY25 loss, maps 2026 catalysts

Annexon reported higher FY25 R&D spend, an EU MAA filing for GBS, $238.3M in cash with runway into H2 2027, and expects pivotal GA data in Q4 2026.

Summary

• Cash, cash equivalents and short-term investments totaled $238.3 million as of December 31, 2025, including $86.3 million in gross proceeds from a November 2025 public offering; operating runway expected into the second half of 2027.
• R&D expenses were $42.7 million in Q4 2025 and $184.7 million for FY 2025 (vs. $119.4 million in FY 2024), driven by the Phase 3 ARCHER II GA trial and global regulatory activities for GBS.
• G&A expenses were $7.6 million in Q4 2025 and $31.7 million for FY 2025 (vs. $34.6 million in FY 2024), reflecting corporate efficiencies.
• Net loss was $48.3 million ($0.28 per share) in Q4 2025 and $208.5 million ($1.34 per share) for FY 2025 (vs. $138.2 million; $1.01 per share in FY 2024).
• Vonaprument Phase 3 ARCHER II trial in GA (n=659) completed enrollment in July 2025; primary endpoint is BCVA 15-letter loss at two consecutive visits through month 15; topline pivotal data expected in Q4 2026; program holds EMA PRIME designation and EMA PDC pilot support.
• Tanruprubart MAA filed with the EMA for GBS; ongoing U.S./EU FORWARD study (including pediatric patients) aims to support a planned U.S. BLA submission in 2026.
• ANX1502, an oral C1s inhibitor, is in an open-label POC study in CAD with BID dosing; update anticipated in 2026 with ongoing PK/PD and hemolysis marker assessments.
• March 2026 Investor Day highlighted vonaprument’s upstream C1q neuroprotective mechanism and Phase 2 vision-preservation data guiding Phase 3 strategy.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive: strong cash runway and tangible regulatory progress (EU MAA, PRIME/PDC) offset higher losses and dilution, with valuation now hinging on pivotal GA data and GBS regulatory outcomes.

Positives

• Cash, cash equivalents and short-term investments of $238.3 million as of December 31, 2025, with expected runway into the second half of 2027.
• EU MAA filed for tanruprubart in GBS with supportive placebo-controlled and real-world evidence; potential to be the first targeted therapy for GBS.
• Vonaprument GA program has a global registration path, EMA PRIME designation, and selection for the EMA PDC pilot; pivotal Phase 3 uses vision preservation (BCVA) as the primary endpoint.
• ARCHER II enrollment completed (659 patients) with patient selection enriched for higher vision-loss risk.
• G&A expenses declined year over year to $31.7 million from $34.6 million, indicating cost discipline.

Negatives

• FY 2025 net loss increased to $208.5 million from $138.2 million; loss per share widened to $1.34 from $1.01.
• R&D expenses rose to $184.7 million from $119.4 million year over year; Q4 2025 R&D remained high at $42.7 million.
• Share dilution indicated by higher weighted-average shares (155.1 million in FY 2025 vs. 137.4 million in FY 2024; 174.6 million in Q4 2025).
• Accumulated deficit increased to $917.4 million; total assets declined to $277.6 million from $350.1 million.
• Interest and other income decreased to $9.7 million in FY 2025 from $15.9 million in FY 2024.

Risks

• Final results from the Phase 3 ARCHER II trial may differ materially from expectations.
• History of net operating losses and the need to obtain additional capital to fund clinical programs.
• Potential delays in clinical trials and the risk that U.S. and foreign regulators may not accept data from trials conducted outside the United States.
• Early stages of clinical development for product candidates increase uncertainty of outcomes.
• Public health crises could negatively affect clinical programs and business operations.
• Regulatory approval and successful commercialization of product candidates are not assured.
• Undesirable side effects or other properties of product candidates may emerge.
• Reliance on third-party suppliers and manufacturers introduces operational risks.
• Outcomes of any future collaboration agreements are uncertain.
• Ability to adequately maintain intellectual property rights is not guaranteed.

Future Outlook

Topline Phase 3 ARCHER II data in GA are expected in Q4 2026; EU MAA review for tanruprubart is underway with a U.S. BLA submission planned in 2026 supported by FORWARD study data; ANX1502 POC update is anticipated in 2026 with potential tablet reformulation to mitigate food effect for later-stage autoimmune development; management intends to focus spend on core late-stage programs with runway into H2 2027.

Management Comments

• “We’re energized by this defining period for Annexon... pioneering a new class of targeted immunotherapies that reshape how neuroinflammation is treated.” — Douglas Love, President and CEO
• “Grounded in robust Phase 2 ARCHER data and strong execution of ARCHER II, we are on track to report topline pivotal data in Q4 2026—the first GA pivotal to evaluate vision preservation as the primary endpoint with an aligned U.S./EU path.”
• “We have filed the EU MAA for tanruprubart and are preparing for potential first targeted therapy approval in GBS; the FORWARD study is designed to support a planned U.S. BLA in 2026.”
• “With a strengthened balance sheet and continued focus on core priorities, we are well-positioned to deliver multiple near-term value-driving catalysts in the year ahead.”

Industry Context

StockSavvy.ai notes that in geographic atrophy, currently approved complement inhibitors such as Apellis’ Syfovre (C3) and Iveric Bio’s Izervay (C5) were approved on lesion-growth endpoints and have not established definitive vision-preservation benefits; Annexon’s C1q-targeting vonaprument is pursuing a vision-preservation primary endpoint with EMA PRIME/PDC support, positioning it uniquely if successful. In GBS, standard care remains IVIg and plasma exchange without a targeted therapy; an approved anti-complement agent like tanruprubart could be practice-changing if efficacy and speed of recovery are robust. For CAD, an oral C1s inhibitor (ANX1502) would be a convenient alternative to IV C1s inhibition (e.g., Sanofi’s Enjaymo) if efficacy and tolerability are confirmed.

Comparison to Industry Standards

• GA: Apellis’ Syfovre (pegcetacoplan, C3) and Iveric Bio’s Izervay (avacincaptad pegol, C5) achieved approval on GA lesion-growth reduction; ARCHER II’s BCVA vision-preservation primary endpoint sets a higher clinical bar relative to peers focused on anatomical endpoints.
• Regulatory: EMA PRIME and PDC engagement for vonaprument compares favorably to standard EU review pathways and may accelerate regulatory interactions versus competitors lacking PRIME.
• GBS: Current standards (IVIg and plasma exchange) are non-targeted; a successful tanruprubart approval would represent the first targeted therapy, improving on function and disability measures observed versus IVIg/PE in RWE cited by the company.
• CAD: Sanofi’s Enjaymo (sutimlimab-jome), an IV anti-C1s antibody, is the benchmark; an effective oral C1s inhibitor (ANX1502) would be a differentiated modality with potential convenience advantages.

Stakeholder Impact

• Shareholders: November 2025 equity raise diluted ownership but extended operating runway into H2 2027.
• Patients: Potential first-in-class targeted therapies in GA (vision preservation) and GBS (rapid functional recovery) could address significant unmet needs.
• Regulators: Active EU engagement (PRIME, PDC, MAA) and planned U.S. BLA indicate increased regulatory interactions through 2026.
• Suppliers/Manufacturers: Continued reliance on third parties presents execution risk as programs scale toward potential approval.

Next Steps

• Report topline Phase 3 ARCHER II GA data in Q4 2026.
• Advance EU MAA review for tanruprubart in GBS.
• Submit U.S. BLA for tanruprubart in 2026 supported by initial FORWARD study data.
• Continue U.S./EU FORWARD study, including pediatric cohorts, to evaluate PK/PD, early functional impact, biomarkers, and safety.
• Provide a 2026 update on the ANX1502 CAD proof-of-concept study and continue PK/PD and hemolysis marker assessments.
• Evaluate potential ANX1502 tablet reformulation to reduce food effect for late-stage development.

Key Dates

Recommendation

With pivotal GA data due in Q4 2026 and an EU MAA filed for GBS ahead of a planned 2026 U.S. BLA, risk-reward skews to upcoming binary catalysts. The cash runway into H2 2027 reduces financing overhang, but higher losses and dilution, coupled with clinical and regulatory uncertainties, support a wait-for-data stance.

Keywords

Annexon, vonaprument, tanruprubart, ANX1502, geographic atrophy, dry AMD, Guillain-Barré syndrome, C1q, C1s, classical complement, ARCHER II, PRIME designation, Product Development Coordinator, MAA, BLA, FORWARD study, cold agglutinin disease, Phase 3, proof of concept, neuroinflammation